Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
Sweden
In shortOncopeptides AB is loss-making, burns cash and holds more cash than debt, with revenue shrinking (−10.1% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -895.8% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -899.3% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -512.5% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -127.1% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 4.23× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 2.25× | 0/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -17.06× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -78.49 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -824.5% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 3 | 0/100 |
| Revenue growth volatility | 219.3% | 0/100 |
| Operating margin volatility | 1633.4% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -35.6% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2024 · change vs prior year
European data comes from annual reports in ESEF format (since 2020). Industry and ticker are not provided by this source.
Annual figures as reported. Hover a bar or point for the exact value.
The last 5 fiscal years from the company's annual reports.
SEK millions; negative values in parentheses.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 |
|---|---|---|---|---|---|
| Revenue | 0 | 118 | 8.4 | 35 | 32 |
| Cost of revenue | 0 | 53 | 0 | (1.1) | 2.7 |
| Gross profit | 0 | 65 | 8.3 | 36 | 29 |
| Research & development | 866 | 680 | 218 | 107 | 121 |
| Operating income | (1,591) | (1,421) | (349) | (253) | (283) |
| Interest expense | 1.5 | 0.9 | 0.9 | 5.8 | 17 |
| Pre-tax income | (1,592) | (1,421) | (338) | (248) | (284) |
| Income tax | 2.3 | 8.9 | 0.3 | – | – |
| Net income | (1,595) | (1,430) | (338) | (249) | (285) |
| Diluted EPS | −kr25.57 | −kr19.00 | kr4.11 | −kr2.76 | −kr1.71 |
−78.49 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
1/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: filings.xbrl.org (ESEF). Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2024 · Data updated Dec 31, 2024